[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100474996":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":19,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":19,"enrollmentInfo":60,"targetDuration":19,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"StingMark Fiducial Marker","EXPERIMENTAL","Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.",[13],"Device: Sting Mark Fiducial Marker",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DEVICE","Sting Mark Fiducial Marker",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Moishe Liberman, MD","CHUM","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","514-890-8000","26214","moishe.liberman@umontreal.ca",[32],{"facility":23,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Montreal","Quebec","H2X 0A9","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-73.58781,45.50884,{"lat":43,"lon":42},[46],{"name":22,"role":27,"phone":28,"phoneExt":47,"email":30},"26832",{"type":49,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100474996","sting-mark-universal-fiducial-marker-system-100474996",false,"NCT05465161","STING MARK Universal Fiducial Marker System","An Ex-Vivo Human Model Study for Proof of Concept, Usability, Reproducibility, Radio-Opacity and Marker Retention","StingMark","Inclusion Criteria:\n\n* Patients undergoing surgical resection of solid organs\n* Recipients of solid organ transplantation\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":61,"type":62},100,"ESTIMATED","INTERVENTIONAL",[65],"NA","Currently available fiducial marker and fiducial insertion strategies are rudimentary, imprecise, not compatible with multiple insertion catheters\u002Fneedles and are overall unreliable. STING-MARK device is the first universal, fully detachable and non-premounted radiopaque fiducial device system. Allowing biopsy prior to insertion, STING-MARK is easily and reliably delivered through-the-needle to the tumor, in order to accurately pinpoint its location for image-guided therapies. This study aims at establishing proof of concept for STING-MARK, by demonstrating its usability, reproducibility, radio-opacity and retention in a variety of clinically-relevant ex vivo organ samples.",[68],"Cancer","2026-04-10",{"date":71,"type":72},"2026-04-13","ACTUAL",{"date":74,"type":72},"2022-02-28",{"date":76,"type":62},"2027-11-01",{"name":5,"class":6},1]